Abstract
Alzheimer's disease (AD) is the most common cause of dementia and a major cause of morbidity and mortality. The greatest risk factor for AD is age and as many countries are experiencing an aging population, the expected rise in AD threatens to have serious medical and socioeconomic impact in the coming decades. The only approved medications for AD are symptomatic and there are no currently available disease modifying treatments. Hence, a disease modifying treatment is desperately needed for AD not only for proper care and management of affected patients, but also to reduce society's socioeconomic burden. Developing novel compounds for any indication is a time, effort, and money consuming endeavor and most treatments never make it to market. Other research and development strategies are needed, especially for the treatment of AD. We provide a review of the current literature in assessing possibilities of repurposing medications currently used for non-AD indications. Many different compounds from many different pharmacological classes have already been studied in an AD context. We provide a "pragmatic drug repurposing score" for each of these compounds based on type of studies conducted, number of possible mechanisms of action, efficacy in AD and other neurodegenerative disease studies, tolerability profile, and their ability to cross the blood brain barrier. The current data suggest several compounds worthy of further study as treatments for AD. Compounds with the highest scores include lithium, minocycline, exenatide, valproic acid, methylene blue, and nicotine.
Keywords: Alzheimer's disease, amyloid, dementia, medications, neurodegenerative disease, repurposing, tau, treatment.
Current Topics in Medicinal Chemistry
Title:Discovering New Treatments for Alzheimer's Disease by Repurposing Approved Medications
Volume: 13 Issue: 18
Author(s): Brian S. Appleby and Jeffrey L. Cummings
Affiliation:
Keywords: Alzheimer's disease, amyloid, dementia, medications, neurodegenerative disease, repurposing, tau, treatment.
Abstract: Alzheimer's disease (AD) is the most common cause of dementia and a major cause of morbidity and mortality. The greatest risk factor for AD is age and as many countries are experiencing an aging population, the expected rise in AD threatens to have serious medical and socioeconomic impact in the coming decades. The only approved medications for AD are symptomatic and there are no currently available disease modifying treatments. Hence, a disease modifying treatment is desperately needed for AD not only for proper care and management of affected patients, but also to reduce society's socioeconomic burden. Developing novel compounds for any indication is a time, effort, and money consuming endeavor and most treatments never make it to market. Other research and development strategies are needed, especially for the treatment of AD. We provide a review of the current literature in assessing possibilities of repurposing medications currently used for non-AD indications. Many different compounds from many different pharmacological classes have already been studied in an AD context. We provide a "pragmatic drug repurposing score" for each of these compounds based on type of studies conducted, number of possible mechanisms of action, efficacy in AD and other neurodegenerative disease studies, tolerability profile, and their ability to cross the blood brain barrier. The current data suggest several compounds worthy of further study as treatments for AD. Compounds with the highest scores include lithium, minocycline, exenatide, valproic acid, methylene blue, and nicotine.
Export Options
About this article
Cite this article as:
Appleby S. Brian and Cummings L. Jeffrey, Discovering New Treatments for Alzheimer's Disease by Repurposing Approved Medications, Current Topics in Medicinal Chemistry 2013; 13 (18) . https://dx.doi.org/10.2174/15680266113136660162
DOI https://dx.doi.org/10.2174/15680266113136660162 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
GEPT Extract Reduces Aβ Deposition by Regulating the Balance Between Production and Degradation of Aβ in APPV717I Transgenic Mice
Current Alzheimer Research Carbon Nano Tubes: Novel Drug Delivery System in Amelioration of Alzheimer’s Disease
Combinatorial Chemistry & High Throughput Screening Anti-platelet Drug-loaded Targeted Technologies for the Effective Treatment of Atherothrombosis
Current Drug Targets Lower CSF Aβ is Associated with HAND in HIV-Infected Adults with a Family History of Dementia
Current HIV Research Cyclooxygenase Inhibitors: Instrumental Drugs to Understand Cardiovascular Homeostasis and Arterial Thrombosis
Cardiovascular & Hematological Disorders-Drug Targets Current and Potential Use of Citrus Essential Oils
Current Organic Chemistry Hypertension in the Elderly: An Evidence-based Review
Current Pharmaceutical Design Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the treatment of Alzheimer’s Disease
Current Neuropharmacology Estrogen Receptor Neurobiology and its Potential for Translation into Broad Spectrum Therapeutics for CNS Disorders
Current Molecular Pharmacology Neuroprotective Effects of Ellagic Acid in Alzheimer's Disease: Focus on Underlying Molecular Mechanisms of Therapeutic Potential
Current Pharmaceutical Design Molecular Targets of Tannic Acid in Alzheimer's Disease
Current Alzheimer Research The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
Current Medicinal Chemistry Interactions of VDAC with Proteins Involved in Neurodegenerative Aggregation: An Opportunity for Advancement on Therapeutic Molecules
Current Medicinal Chemistry Diagnosis, Treatment, and New Developments in Preeclampsia
Current Women`s Health Reviews Editorial (Thematic Issue: Translational Alzheimer’s Disease Research)
Current Alzheimer Research HDL Genetic Defects
Current Pharmaceutical Design A<sub>3</sub> Adenosine Receptor: A Plausible Therapeutic Target for Cardio-Protection in Diabetes
Recent Patents on Cardiovascular Drug Discovery Heart Valve Lesions In The Antiphospholipid Syndrome
Current Rheumatology Reviews Editorial
Current Medical Imaging Neurodegeneration and the Heat Shock Protein 70 Machinery: Implications for Therapeutic Development
Current Topics in Medicinal Chemistry